Renal Cell Carcinoma

Lenvatinib in combination with everolimus improved progression-free survival in patients with advanced renal cell carcinoma compared with sunitinib, meeting the primary end point of the phase 3 KEYNOTE-581/CLEAR clinical trial. Pembrolizumab added to lenvatinib, another experimental arm of the trial, also achieved a satisfactory overall response rate, meeting a key secondary end point.

Investigators of the CheckMate 920 trial found no differences in safety signals or responses with modified dosing of nivolumab and ipilimumab compared with the standard dose in patients with advanced renal cell carcinoma treated in the frontline.

During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.

Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.

Significant overall survival and progression-free survival benefits were observed with combination regimens containing immunotherapy in combination with a tyrosine kinase inhibitor, along with tolerable safety in patients with renal cell carcinoma to Suzanne Cole, MD, FACP noted, however, that the cost of these combination can dim the light on the advantages.

Elizabeth Wulff-Burchfield, MD, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.

In patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy, the combination of lenvatinib and pembrolizumab achieved antitumor responses, according to results from a phase 2 trial.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed key results from the CheckMate-9ER trial in advanced renal cell carcinoma, as well as ongoing trials with the potential to move the landscape further along.

Lenvatinib plus everolimus demonstrated anti-tumor activity as treatment of patients with advanced non-clear cell renal cell carcinoma in the frontline setting, according to findings from a phase 2 clinical trial.

Based on results from the phase 2 OMNIVORE study, the response-based strategy achieved no complete responses and a low partial response/complete response conversion in advanced renal cell carcinoma.

During a Targeted Oncology Case Based Peer Perspective event, Chung-Han Lee, MD, PhD, discussed the case of a 57-year-old woman with clear cell renal cell carcinoma.

Ulka Vaishampayan, MD, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib plus nivolumab as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.

In an interview with Targeted Oncology, Laurence Albiges, MD, PhD, discussed the updated findings for the combination of nivolumab and ipilimumab as treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma.

Bradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.

In an interview with Targeted Oncology, Bradley McGregor, MD, discussed the findings from the CheckMate-9ER study of nivolumab and cabozantinib as treatment of patients with advanced renal cell carcinoma, as well as the health-related QoL data supporting the use of this combination.

The FDA granted a Priority Review designation to the combination of nivolumab plus cabozantinib for the treatment of patients with advanced renal cell carcinoma.

In an interview with Targeted Oncology, Rana R. McKay, MD, discussed the findings from the CheckMate-9ER study of nivolumab plus cabozantinib in patients with advanced or metastatic renal cell carcinoma who had not been previously treated.

Rana R. McKay, MD, discusses the combination of nivolumab and cabozantinib versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

In a post hoc analysis of the randomized phase 3 SURTIME trial of patients with metastatic renal cell carcinoma, early treatment with sunitinib demonstrated better control over the disease as well as detection of progression before planned cytoreductive nephrectomy.